AbbVie's migraine treatment meets late-stage study goal

ABBV•2026-09-10

Late-stage study meets main goal

Sept. 10 (Reuters) - AbbVie ABBV.N said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive treatment of menstrual migraine in adults.

AbbVie's migraine treatment meets late-stage study goal

Late-stage study meets main goal

Related News

Nasdaq trade halt <AHMA.O> volatility trading pause at 09:32 AM

Principal Financial Group Inc <PFG.O>: UBS raises target price to $120 from $98

Avalanche Treasury appoints Virginia Gambale to board

Greece's Tsakos Energy Q2 profit jumps over 500% on higher tanker rates, vessel sales

Signet Jewelers Limited <SIG.N>: UBS raises target price to $136 from $122